Current Advances in the Treatment of BRAF-Mutant Melanoma

威罗菲尼 达布拉芬尼 曲美替尼 黑色素瘤 医学 MEK抑制剂 癌症研究 MAPK/ERK通路 免疫疗法 癌症 肿瘤科 转移性黑色素瘤 内科学 激酶 生物 细胞生物学
作者
Hima Patel,Nour Yacoub,Rosalin Mishra,Aaron White,Long Yuan,Samar Alanazi,Joan T. Garrett
出处
期刊:Cancers [Multidisciplinary Digital Publishing Institute]
卷期号:12 (2): 482-482 被引量:173
标识
DOI:10.3390/cancers12020482
摘要

Melanoma is the most lethal form of skin cancer. Melanoma is usually curable with surgery if detected early, however, treatment options for patients with metastatic melanoma are limited and the five-year survival rate for metastatic melanoma had been 15-20% before the advent of immunotherapy. Treatment with immune checkpoint inhibitors has increased long-term survival outcomes in patients with advanced melanoma to as high as 50% although individual response can vary greatly. A mutation within the MAPK pathway leads to uncontrollable growth and ultimately develops into cancer. The most common driver mutation that leads to this characteristic overactivation in the MAPK pathway is the B-RAF mutation. Current combinations of BRAF and MEK inhibitors that have demonstrated improved patient outcomes include dabrafenib with trametinib, vemurafenib with cobimetinib or encorafenib with binimetinib. Treatment with BRAF and MEK inhibitors has met challenges as patient responses began to drop due to the development of resistance to these inhibitors which paved the way for development of immunotherapies and other small molecule inhibitor approaches to address this. Resistance to these inhibitors continues to push the need to expand our understanding of novel mechanisms of resistance associated with treatment therapies. This review focuses on the current landscape of how resistance occurs with the chronic use of BRAF and MEK inhibitors in BRAF-mutant melanoma and progress made in the fields of immunotherapies and other small molecules when used alone or in combination with BRAF and MEK inhibitors to delay or circumvent the onset of resistance for patients with stage III/IV BRAF mutant melanoma.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
水牛完成签到,获得积分10
1秒前
叮咚咚发布了新的文献求助10
1秒前
1秒前
暴龙战士发布了新的文献求助10
2秒前
沐木关注了科研通微信公众号
2秒前
UNIQUE完成签到,获得积分10
3秒前
牛初辰完成签到 ,获得积分10
3秒前
小二郎的应助被轩仔子采纳,获得10
3秒前
Yes完成签到,获得积分10
4秒前
可妍昇发布了新的文献求助10
5秒前
传奇3的应助被xiaolong采纳,获得10
5秒前
6秒前
fanyy完成签到,获得积分10
6秒前
7秒前
coco完成签到,获得积分10
9秒前
昏睡的坚果完成签到 ,获得积分10
9秒前
Yu完成签到,获得积分10
10秒前
transition完成签到,获得积分10
10秒前
简单山水发布了新的文献求助10
11秒前
12秒前
13秒前
小Z完成签到,获得积分10
14秒前
14秒前
xuliang完成签到,获得积分10
14秒前
15秒前
沐木发布了新的文献求助30
17秒前
yrz完成签到,获得积分20
18秒前
斯文败类的应助被xwx采纳,获得10
19秒前
徐丹枫发布了新的文献求助10
19秒前
19秒前
乌龙茶发布了新的文献求助10
19秒前
我是老大的应助被科研通管家采纳,获得10
19秒前
深情安青的应助被科研通管家采纳,获得10
20秒前
20秒前
FashionBoy的应助被科研通管家采纳,获得50
20秒前
情怀的应助被科研通管家采纳,获得10
20秒前
Hase的应助被科研通管家采纳,获得30
20秒前
秋风的应助被科研通管家采纳,获得10
20秒前
华仔的应助被科研通管家采纳,获得10
20秒前
酷波er的应助被科研通管家采纳,获得10
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181767
求助须知:如何正确求助?哪些是违规求助? 9571480
关于积分的说明 21818225
捐赠科研通 7778030
什么是DOI,文献DOI怎么找? 3433524
关于科研通互助平台的介绍 2557696
邀请新用户注册赠送积分活动 2479598